31,074 Kenvue Inc. $KVUE Shares Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. raised its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 9.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 348,133 shares of the company’s stock after purchasing an additional 31,074 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Kenvue were worth $6,235,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Kenvue in the 2nd quarter worth about $2,882,279,000. Pentwater Capital Management LP purchased a new stake in shares of Kenvue during the 2nd quarter valued at about $977,094,000. HBK Investments L P lifted its holdings in shares of Kenvue by 33.3% in the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after acquiring an additional 7,000,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Kenvue by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock valued at $383,938,000 after acquiring an additional 196,981 shares during the last quarter. Finally, Amundi lifted its holdings in shares of Kenvue by 41.2% in the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock valued at $353,216,000 after acquiring an additional 5,392,413 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

KVUE stock opened at $19.31 on Friday. Kenvue Inc. has a twelve month low of $14.06 and a twelve month high of $20.13. The stock has a market capitalization of $37.09 billion, a price-to-earnings ratio of 21.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.48. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm’s fifty day simple moving average is $18.41 and its two-hundred day simple moving average is $18.23.

Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business’s revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is presently 95.45%.

Wall Street Analyst Weigh In

KVUE has been the subject of several recent research reports. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group raised their price objective on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research note on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Finally, HSBC dropped their target price on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Ten analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.29.

Get Our Latest Stock Analysis on Kenvue

About Kenvue

(Free Report)

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.

Read More

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.